Cardiology

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

Lipid screening after bulk orders and outreach letters increased significantly at 3 months, but supplemental text messaging had no further impact.

The January 2025 cardiology month in review highlights new NDA acceptances, clearance of the first Lp(a) test in molar units, and national trends in preventive aspirin use.

A study indicated that telomere length may not directly cause age-related brain diseases, but healthier lifestyles could counteract the harmful effects of shorter telomeres.

Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

Results from the Phase 3 LIBerate-HoFH trial found LDL-C responses generally similar between patients treated with lerodalcibep and evolocumab.

Awarded to Roche, the Tina-quant® Lipoprotein (a) Gen.2 Molarity assay will be the first 510(k) cleared test measuring Lp(a) in nanomoles per liter (nmol/L).

Only 7% of patients presenting to US emergency departments received cardiac biomarker testing, with 2.8% diagnosed with ACS.

The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 14, 2025.

Enobosarm led to a statistically significant benefit in the protection of lean mass in patients with overweight or obesity receiving semaglutide.

Medicaid-insured heart transplant recipients reported worse survival and higher risk of cardiac allograft vasculopathy over 5 years.

Abelacimab achieved notably lower levels of free factor XI and fewer bleeding events than standard-of-care rivaroxaban in the Phase 2b trial.

Grade 2 or 3 cardiac uptake showed a 5-fold higher risk of cardiovascular death compared to grade 1 in asymptomatic ATTR cardiac amyloid infiltration.

Self-reported primary prevention aspirin use decreased among adults with both low and high ASCVD risk after the release of evidence-based guidelines.

Increases in oxidized HDL levels were linked to HFpEF in new analyses, suggesting reduced antioxidant HDL function is present in this patient population.

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 18, 2025.

Anti-CGRP monoclonal antibodies for migraine prevention were not linked to increased cardiovascular risk, per a Medicare study, addressing earlier safety concerns.

A cohort study with 14 years of follow-up found monogenic and polygenic mechanisms influencing LDL-C and incident T2D risk inversely associated.

AHN's specialized Shock Team at Allegheny General Hospital works to fight against cardiogenic shock.

Subjective poor sleep quality is tied to greater systolic blood pressure in adults ≤ 49 years with optimal sleep duration, compared with adults ≥ 50 years.

Nearly half of patients with acute coronary syndrome in a single-center analysis exhibited iron deficiency, with anemia linked to a greater impact on mortality.